Takeda Oncology
Jillian West is currently serving as the Associate Director, Program Management Lead at Takeda Oncology since June 2023, following a tenure as Senior Program Manager in Oncology at GSK from July 2021 to June 2023. Prior to GSK, Jillian was a Project Manager in US Medical for Dupilumab at Sanofi from January 2020 to July 2021. Jillian gained significant experience at Harvard Medical School from December 2015 to January 2020 as Program Manager for Educational Development & Accreditation, where responsibilities included managing over 350 educational activities annually and developing certification processes that benefited over 5,000 learners. Earlier experience includes working as a Meeting Manager at the Professional Relations and Research Institute from June 2007 to November 2015, focusing on the planning and execution of large-scale meetings for surgical associations. Jillian holds a Master of Liberal Arts in Business Administration and Management from Harvard Extension School (2017-2020) and a Bachelor of Science in Hospitality and Tourism Management from the University of Massachusetts Amherst (2003-2007).
This person is not in any teams
This person is not in any offices
Takeda Oncology
21 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.